1. Home
  2. APPF vs RYTM Comparison

APPF vs RYTM Comparison

Compare APPF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AppFolio Inc.

APPF

AppFolio Inc.

HOLD

Current Price

$148.25

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$107.03

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPF
RYTM
Founded
2006
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.8B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
APPF
RYTM
Price
$148.25
$107.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
14
Target Price
$286.78
$131.14
AVG Volume (30 Days)
380.6K
765.9K
Earning Date
04-23-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
1.18
N/A
Revenue
$950,822,000.00
N/A
Revenue This Year
$19.69
$55.34
Revenue Next Year
$16.70
$86.06
P/E Ratio
$124.20
N/A
Revenue Growth
19.72
N/A
52 Week Low
$142.56
$62.29
52 Week High
$325.90
$122.20

Technical Indicators

Market Signals
Indicator
APPF
RYTM
Relative Strength Index (RSI) 40.87 74.97
Support Level $145.78 $97.65
Resistance Level $168.43 $113.03
Average True Range (ATR) 7.81 4.92
MACD -2.07 2.17
Stochastic Oscillator 18.47 84.20

Price Performance

Historical Comparison
APPF
RYTM

About APPF AppFolio Inc.

AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: